An analyst from Piper Sandler maintained AbbVie (NYSE: ABBV) at 'overweight' with a price target of $180.00 from a prior price target of %currency%%price%. Prior to this rating, AbbVie had...
It was announced yesterday that AbbVie (NYSE:ABBV) is acquiring neuroscience biotech firm Cerevel Therapeutics (CERE) for $8.7 billion. Elsewhere in the biotech sector, Karuna Therapeutics...
The obesity drug market is red-hot thanks to the huge success of Novo Nordisk's (NYSE:NVO) Ozempic and Wegovy. On Monday, Roche (RHHBY (OTC:RHHBY)) threw its hat into the ring with the $2.7...
(Updated - December 7, 2023 5:18 AM EST) AbbVie Inc . (NYSE:ABBV) announced it will acquire Cerevel Therapeutics (CERE) in a deal that will the former acquire the latter's robust...
The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's "robust" neuroscience pipeline adds medications that may...
AbbVie Inc . (NYSE:ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience....
(Updated - November 30, 2023 12:12 PM EST) Investing.com -- Main U.S. indexes were mixed on Thursday after inflation and jobs data didn’t change investors' opinion on the timing of Fed rate...
AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.The transaction values ImmunoGen...
Immunogen (IMGN) to Resume Trading at 8 a.m. Following News of Takeover by AbbVie (ABBV)Earlier: AbbVie Inc (NYSE:ABBV). (ABBV) and ImmunoGen (NASDAQ:IMGN), Inc. (IMGN) today...
AbbVie (NYSE:ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression,...
AbbVie (ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific...
Investors are advised to keep a close watch on AbbVie Inc (NYSE:ABBV).'s leverage strategy as the pharmaceutical giant navigates a complex financial landscape characterized by a...
New York, USA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Ocular Hypertension Market Size and Share to Increase by 2032, Asserts DelveInsight | Leading Companies in the Market- Nicox, Glaukos,...
Eli Lilly (NYSE:LLY)'s recent foray into the weight-loss market with the approval of its diabetes drug Mounjaro for weight management signals a strategic expansion for the pharmaceutical...
BOSTON - Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX). experienced a decline for the third straight day, closing at $343.00, a 1.81% drop during Thursday's trading session. The...
AbbVie (NYSE:ABBV) today announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of...
In a recent breakthrough for Eli Lilly and Company (NYSE:LLY), its new weight loss drug, Zepbound, received approval from the Food and Drug Administration (FDA) on Wednesday. The drug...
Investing.com -- The Dow closed lower Thursday, as Federal Reserve chairman Jerome Powell dealt a blow to bets on sooner rather later rate cuts after signaling that the Fed isn't ready to...
An analyst from Deutsche Bank initiated coverage of AbbVie (NYSE: ABBV) at 'hold' with a price target of $150.00. Prior to this rating, AbbVie had 16 buy ratings, 12 hold ratings, and 1...
New York, USA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing Therapies -...
These seven top Dividend Aristocrats all are trading at very reasonable levels, pay dependable dividends and are solid and safe ideas despite facing some headwinds this year. The post 7...
An analyst from DZ Bank maintained AbbVie (NYSE: ABBV) at 'buy' with a price target of $167.00 from a prior price target of %currency%%price%. Prior to this rating, AbbVie had 16 buy...
Investing.com -- Shares in AbbVie (NYSE:ABBV) rose on Monday after analysts at Barclays (LON:BARC) raised their rating and price target for the drugmaker, calling a temporary drop in the...
An analyst from Morgan Stanley maintained AbbVie (NYSE: ABBV) at 'overweight' with a price target of $196.00 from a prior price target of %currency%%price%. Prior to this rating, AbbVie...
NEXGEL, Inc. (NXGL) today announced that its subsidiary, CG Converting and Packaging, has executed a supply agreement with AbbVie Inc. (ABBV), a global biopharmaceutical company to be a...
(Updated - October 30, 2023 7:35 AM EDT) Barclays (LON:BARC) analysts upgraded Abbvie (ABBV) from Equalweight to Overweight with a price target of $170.00 (from $160.00).The analysts...
Pharmaceutical giant AbbVie (NYSE:ABBV) reported robust financial performance for Q3 2023, outperforming expectations, according to the recent earnings call. The company's growth platform,...
AbbVie (NYSE:ABBV) shares dipped at the open Friday despite reporting its latest quarterly earnings that beat consensus expectations. The pharmaceutical firm reported Q3 EPS of $2.95, $0.08...
Investing.com - AbbVie (NYSE: ABBV) reported third quarter EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93B versus the consensus...
Before U.S. markets open on Friday, the country's two largest oil and gas companies will report earnings. The post Earnings Previews for AbbVie, Chevron, Exxon Mobil; All Reporting Friday...
Allergan Aesthetics, an AbbVie company (ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment...
These seven top Dividend Aristocrats have been out of favor. Yet they are all trading at quite reasonable levels, pay generous and dependable dividends, and are solid and safe ideas in the...
AbbVie (NYSE:ABBV) is poised to announce its Q3 2023 results on Thursday, October 27, following a previous quarter that saw an earnings surprise of 4.30%. This announcement comes as the...
(Updated - October 20, 2023 4:43 AM EDT) UBS assumes coverage on Abbvie (ABBV) with a Neutral rating and a price target of $150.00.The analysts comment "We assume coverage of AbbVie...
Eli Lilly (NYSE:LLY)'s experimental drug, mirikizumab (Omvoh), has shown significant potential in treating moderate-to-severe Crohn's disease (CD) according to the phase III VIVID-1 study...
On October 11, 2023, AbbVie (ABBV) expanded the size of its Board of Directors (the “Board”) from eleven directors to thirteen directors and appointed Jennifer Davis as a Class II director...
AbbVie (ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline...
An analyst from Morgan Stanley maintained AbbVie (NYSE: ABBV) at 'overweight' with a price target of $193.00 from a prior price target of %currency%%price%. Prior to this rating, AbbVie...
AbbVie (ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from...
AbbVie (ABBV) Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2023 are expected to include acquired IPR&D and milestones expense of $66 million on a pre-tax...
AbbVie (ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate...
Featured stocks include AbbVie and Johnson & Johnson.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
